Form 4: Quest Diagnostics SVP Increases Stake with Share Acquisition

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reported the acquisition of 27 shares of common stock, signaling continued confidence in the company.

Summary

• Karthik Kuppusamy, Senior Vice President of Clinical Solutions at Quest Diagnostics Inc. (DGX), acquired 27 shares of common stock.
• The transaction occurred on July 21, 2025, with shares acquired at a price of $167.498 per share.
• The acquisition was made pursuant to a dividend reinvestment plan administered by the reporting person's broker and was voluntarily reported early on this Form 4.
• Following this transaction, Mr. Kuppusamy beneficially owns 10,660 shares directly.
• Additionally, Mr. Kuppusamy indirectly owns 358 shares through a Trust and 1,629 shares through the Company's 401(k) Plan, which includes exempt purchases made under the Company's stock purchase plan since the last Form 4 filing.

Sentiment

Score: 7

Explanation: The acquisition of shares by a senior executive is a positive indicator of confidence, though the relatively small number of shares acquired limits the overall impact on sentiment.

Positives

• An insider, the SVP of Clinical Solutions, acquiring additional shares indicates management's confidence in the company's future performance and valuation.
• The acquisition through a dividend reinvestment plan and company stock purchase plan suggests a long-term investment strategy and alignment with shareholder interests.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider acquisition implicitly suggests a positive outlook from management.

Industry Context

This insider transaction reflects an individual executive's investment decision within the healthcare diagnostics industry. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The reported transaction is a related party transaction, as it involves an acquisition of company stock by a senior officer of Quest Diagnostics.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign, potentially increasing confidence in the company's stock.
• Employees may see this as a sign of stability and positive internal outlook from leadership.

Key Dates

Recommendation

While the insider acquisition by a senior executive is a positive signal, indicating confidence in Quest Diagnostics' future, the relatively small number of shares acquired does not fundamentally alter the company's financial outlook or strategic position. It reinforces a 'hold' recommendation, suggesting that existing investors may maintain their positions based on this positive, albeit minor, vote of confidence from management.

Keywords

Quest Diagnostics, DGX, insider trading, Form 4, stock acquisition, executive ownership, beneficial ownership, dividend reinvestment plan, 401(k)